T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H2 2019
T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H2 2019
SUMMARY
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H2 2019, outlays comprehensive information on the T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - T-Cell surface glycoprotein CD3 epsilon chain also known as CD3E is a polypeptide encoded by the CD3E gene. T-cell surface glycoprotein CD3 epsilon chain interacts with TOP2B, CD3EAPand NCK2. The CD3 complex mediates signal transduction, resulting in T-cell activation and proliferation. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2, 3 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Metabolic Disorders, Gastrointestinal, Genetic Disorders, Immunology and Infectious Disease which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Multiple Sclerosis, Type 1 Diabetes (Juvenile Diabetes), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Amyotrophic Lateral Sclerosis, B-Cell Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Inflammation, Crohn's Disease (Regional Enteritis), Down Syndrome, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Hepatitis B, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Lymphoblastic Lymphoma, Multiple Myeloma (Kahler Disease), Nodal Marginal Zone B-Cell Lymphoma, Non-Alcoholic Steatohepatitis (NASH), Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Solid Tumor, Splenic Marginal Zone B-Cell Lymphoma, Traumatic Brain Injury and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Furthermore, this report also reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) pipeline Target constitutes close to 13 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report T Cell Surface Glycoprotein CD3 Epsilon Chain - Pipeline Review, H2 2019, outlays comprehensive information on the T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - T-Cell surface glycoprotein CD3 epsilon chain also known as CD3E is a polypeptide encoded by the CD3E gene. T-cell surface glycoprotein CD3 epsilon chain interacts with TOP2B, CD3EAPand NCK2. The CD3 complex mediates signal transduction, resulting in T-cell activation and proliferation. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2, 3 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Metabolic Disorders, Gastrointestinal, Genetic Disorders, Immunology and Infectious Disease which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Multiple Sclerosis, Type 1 Diabetes (Juvenile Diabetes), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Amyotrophic Lateral Sclerosis, B-Cell Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Inflammation, Crohn's Disease (Regional Enteritis), Down Syndrome, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Hepatitis B, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Lymphoblastic Lymphoma, Multiple Myeloma (Kahler Disease), Nodal Marginal Zone B-Cell Lymphoma, Non-Alcoholic Steatohepatitis (NASH), Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Solid Tumor, Splenic Marginal Zone B-Cell Lymphoma, Traumatic Brain Injury and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Furthermore, this report also reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)
- The report reviews T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics and enlists all their major and minor projects
- The report assesses T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Overview
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Companies Involved in Therapeutics Development
Amgen Inc
Celgene Corp
F. Hoffmann-La Roche Ltd
Numab Innovation AG
Provention Bio Inc
SYNIMMUNE GmbH
Tiziana Life Sciences Plc
Tolerx, Inc. (Inactive)
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Drug Profiles
AMG-330 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibodies to Target CD3, CD16 and HBsAg for HBV Infection and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Target CD3E and PSMA for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
blinatumomab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EM-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
foralumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to target CD3E and Cells Expressing NKG2D for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
otelixizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pasotuxizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-7082859 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TACSYN - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teplizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Dormant Products
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Product Development Milestones
Featured News & Press Releases
Nov 06, 2019: Roche to present on its Non-Hodgkin Lymphoma drug candidate CD20-TCB at the American Society of Hematology 2019 Annual Meeting
Oct 24, 2019: Provention Bio announces PRV-031 (Teplizumab) granted PRIME designation by the European Medicines Agency
Sep 25, 2019: Amgen stops Blincyto’s Phase III paediatric ALL trials early
Sep 24, 2019: Provention Bio reiterates regulatory strategy for PRV-031 and announces completion of follow-on financing
Sep 16, 2019: Tiziana Life Sciences announces FDA approval to initiate phase I clinical trial with orally administered foralumab in healthy volunteers
Sep 10, 2019: Tiziana reports phase 1 clinical data demonstrating nasal treatment with foralumab was well-tolerated and produced positive trend in biomarkers of immunomodulation and anti-inflammation in healthy volunteers
Aug 20, 2019: Provention Bio announces key addition to its leadership team
Aug 05, 2019: Provention Bio announces breakthrough therapy designation for Teplizumab (PRV-031) for the prevention or delay of clinical type 1 diabetes in at-risk individuals
Jul 01, 2019: Tiziana Life Sciences provides update on development on Foralumab
Jul 01, 2019: Independent Third Party Article in New England Journal of Medicine reports on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays in progression of Type 1 Diabetes
Jun 24, 2019: Newly published article reporting clinical activity of orally administered OKT3, a mouse anti-CD3 monoclonal antibody, in moderate to severe ulcerative colitis patients, supports Tiziana's oral monoclonal antibody platform
Jun 15, 2019: Amgen announces BLINCYTO (blinatumomab) five-year overall survival data At EHA 2019
Jun 09, 2019: A Single course of Provention's PRV-031 (Teplizumab) delays Type 1 Diabetes Onset in High-Risk Individuals by at least two years
Jun 02, 2019: Amgen presented data on its investigational drug AMG 212 at ASCO 2019
May 29, 2019: Amgen to present on its prostate cancer drug candidate AMG 212 at 55th Annual Meeting Of The American Society Of Clinical Oncology (ASCO)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Overview
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Companies Involved in Therapeutics Development
Amgen Inc
Celgene Corp
F. Hoffmann-La Roche Ltd
Numab Innovation AG
Provention Bio Inc
SYNIMMUNE GmbH
Tiziana Life Sciences Plc
Tolerx, Inc. (Inactive)
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Drug Profiles
AMG-330 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibodies to Target CD3, CD16 and HBsAg for HBV Infection and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Target CD3E and PSMA for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
blinatumomab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EM-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
foralumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to target CD3E and Cells Expressing NKG2D for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
otelixizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pasotuxizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-7082859 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TACSYN - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teplizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Dormant Products
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Product Development Milestones
Featured News & Press Releases
Nov 06, 2019: Roche to present on its Non-Hodgkin Lymphoma drug candidate CD20-TCB at the American Society of Hematology 2019 Annual Meeting
Oct 24, 2019: Provention Bio announces PRV-031 (Teplizumab) granted PRIME designation by the European Medicines Agency
Sep 25, 2019: Amgen stops Blincyto’s Phase III paediatric ALL trials early
Sep 24, 2019: Provention Bio reiterates regulatory strategy for PRV-031 and announces completion of follow-on financing
Sep 16, 2019: Tiziana Life Sciences announces FDA approval to initiate phase I clinical trial with orally administered foralumab in healthy volunteers
Sep 10, 2019: Tiziana reports phase 1 clinical data demonstrating nasal treatment with foralumab was well-tolerated and produced positive trend in biomarkers of immunomodulation and anti-inflammation in healthy volunteers
Aug 20, 2019: Provention Bio announces key addition to its leadership team
Aug 05, 2019: Provention Bio announces breakthrough therapy designation for Teplizumab (PRV-031) for the prevention or delay of clinical type 1 diabetes in at-risk individuals
Jul 01, 2019: Tiziana Life Sciences provides update on development on Foralumab
Jul 01, 2019: Independent Third Party Article in New England Journal of Medicine reports on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays in progression of Type 1 Diabetes
Jun 24, 2019: Newly published article reporting clinical activity of orally administered OKT3, a mouse anti-CD3 monoclonal antibody, in moderate to severe ulcerative colitis patients, supports Tiziana's oral monoclonal antibody platform
Jun 15, 2019: Amgen announces BLINCYTO (blinatumomab) five-year overall survival data At EHA 2019
Jun 09, 2019: A Single course of Provention's PRV-031 (Teplizumab) delays Type 1 Diabetes Onset in High-Risk Individuals by at least two years
Jun 02, 2019: Amgen presented data on its investigational drug AMG 212 at ASCO 2019
May 29, 2019: Amgen to present on its prostate cancer drug candidate AMG 212 at 55th Annual Meeting Of The American Society Of Clinical Oncology (ASCO)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by Celgene Corp, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by Numab Innovation AG, H2 2019
Pipeline by Provention Bio Inc, H2 2019
Pipeline by SYNIMMUNE GmbH, H2 2019
Pipeline by Tiziana Life Sciences Plc, H2 2019
Pipeline by Tolerx, Inc. (Inactive), H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by Celgene Corp, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by Numab Innovation AG, H2 2019
Pipeline by Provention Bio Inc, H2 2019
Pipeline by SYNIMMUNE GmbH, H2 2019
Pipeline by Tiziana Life Sciences Plc, H2 2019
Pipeline by Tolerx, Inc. (Inactive), H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Amgen Inc
Celgene Corp
F. Hoffmann-La Roche Ltd
Numab Innovation AG
Provention Bio Inc
SYNIMMUNE GmbH
Tiziana Life Sciences Plc
Tolerx, Inc. (Inactive)
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Amgen Inc
Celgene Corp
F. Hoffmann-La Roche Ltd
Numab Innovation AG
Provention Bio Inc
SYNIMMUNE GmbH
Tiziana Life Sciences Plc
Tolerx, Inc. (Inactive)
